Literature DB >> 25099582

PALB2 mutations and breast-cancer risk.

Michele K Evans1, Dan L Longo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25099582      PMCID： PMC4669041          DOI： 10.1056/NEJMe1405784

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  Novel germline PALB2 truncating mutations in African American breast cancer patients.

Authors:  Yonglan Zheng; Jing Zhang; Qun Niu; Dezheng Huo; Olufunmilayo I Olopade
Journal:  Cancer       Date:  2011-08-26       Impact factor: 6.860

2.  Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer.

Authors:  Silvia Casadei; Barbara M Norquist; Tom Walsh; Sunday Stray; Jessica B Mandell; Ming K Lee; John A Stamatoyannopoulos; Mary-Claire King
Journal:  Cancer Res       Date:  2011-02-01       Impact factor: 12.701

Review 3.  Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology.

Authors:  Shane R Stecklein; Roy A Jensen
Journal:  Transl Res       Date:  2012-02-09       Impact factor: 7.012

Review 4.  BRCA1 and BRCA2: different roles in a common pathway of genome protection.

Authors:  Rohini Roy; Jarin Chun; Simon N Powell
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

5.  Germline mutations in PALB2 in African-American breast cancer cases.

Authors:  Yuan Chun Ding; Linda Steele; Li-Hao Chu; Karen Kelley; Helen Davis; Esther M John; Gail E Tomlinson; Susan L Neuhausen
Journal:  Breast Cancer Res Treat       Date:  2010-11-27       Impact factor: 4.872

Review 6.  PALB2/FANCN: recombining cancer and Fanconi anemia.

Authors:  Marc Tischkowitz; Bing Xia
Journal:  Cancer Res       Date:  2010-09-21       Impact factor: 12.701

7.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

Authors:  Nuala McCabe; Nicholas C Turner; Christopher J Lord; Katarzyna Kluzek; Aneta Bialkowska; Sally Swift; Sabrina Giavara; Mark J O'Connor; Andrew N Tutt; Małgorzata Z Zdzienicka; Graeme C M Smith; Alan Ashworth
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

8.  Breast-cancer risk in families with mutations in PALB2.

Authors:  Antonis C Antoniou; Silvia Casadei; Tuomas Heikkinen; Daniel Barrowdale; Katri Pylkäs; Jonathan Roberts; Andrew Lee; Deepak Subramanian; Kim De Leeneer; Florentia Fostira; Eva Tomiak; Susan L Neuhausen; Zhi L Teo; Sofia Khan; Kristiina Aittomäki; Jukka S Moilanen; Clare Turnbull; Sheila Seal; Arto Mannermaa; Anne Kallioniemi; Geoffrey J Lindeman; Saundra S Buys; Irene L Andrulis; Paolo Radice; Carlo Tondini; Siranoush Manoukian; Amanda E Toland; Penelope Miron; Jeffrey N Weitzel; Susan M Domchek; Bruce Poppe; Kathleen B M Claes; Drakoulis Yannoukakos; Patrick Concannon; Jonine L Bernstein; Paul A James; Douglas F Easton; David E Goldgar; John L Hopper; Nazneen Rahman; Paolo Peterlongo; Heli Nevanlinna; Mary-Claire King; Fergus J Couch; Melissa C Southey; Robert Winqvist; William D Foulkes; Marc Tischkowitz
Journal:  N Engl J Med       Date:  2014-08-07       Impact factor: 91.245

9.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Authors:  Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504
  9 in total
  6 in total

1.  BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer.

Authors:  Ming Cui; Xian-Shu Gao; Xiaobin Gu; Wei Guo; Xiaoying Li; Mingwei Ma; Shangbin Qin; Xin Qi; Mu Xie; Chuan Peng; Yun Bai
Journal:  Oncotarget       Date:  2017-06-20

2.  Gene-Specific Genetic Complementation between Brca1 and Cobra1 During Mouse Mammary Gland Development.

Authors:  Huai-Chin Chiang; Xiaowen Zhang; Xiayan Zhao; Chi Zhang; Jerry Chen; Paula Garza; Sabrina Smith; Thomas Ludwig; Richard J Baer; Rong Li; Yanfen Hu
Journal:  Sci Rep       Date:  2018-02-09       Impact factor: 4.379

3.  Prevalence of deleterious mutations among patients with breast cancer referred for multigene panel testing in a Romanian population.

Authors:  Iulian Gabriel Goidescu; Gabriela Caracostea; Dan Tudor Eniu; Florin Vasile Stamatian
Journal:  Clujul Med       Date:  2018-04-25

4.  Mutational Characterization of Colorectal Cancer from Korean Patients with Targeted Sequencing.

Authors:  Jongmin Lee; Sangtae Choi; Donghae Jung; YunJae Jung; Jung Ho Kim; Sungwon Jung; Won-Suk Lee
Journal:  J Cancer       Date:  2021-10-28       Impact factor: 4.207

5.  Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and normal tissue protection in radiotherapy.

Authors:  Jac A Nickoloff; Lynn Taylor; Neelam Sharma; Takamitsu A Kato
Journal:  Cancer Drug Resist       Date:  2021-06-19

6.  Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.

Authors:  Jin-Sun Ryu; Hye-Young Lee; Eun Hae Cho; Kyong-Ah Yoon; Min-Kyeong Kim; Jungnam Joo; Eun-Sook Lee; Han-Sung Kang; Seeyoun Lee; Dong Ock Lee; Myong Cheol Lim; Sun-Young Kong
Journal:  Cancer Sci       Date:  2020-09-02       Impact factor: 6.716
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.